Article Text

Download PDFPDF
208 Immune checkpoint inhibitor-related neurotoxicity: a case series
  1. Rachel Brown1,
  2. Lewis Au2,
  3. Lavinia Spain2,
  4. Andrew Furness2,
  5. Jeremy Rees3,
  6. Alex Rossor1,
  7. Emma Morris4,
  8. Michael Zandi1,
  9. Michael Lunn1,
  10. James Larkin2,
  11. Samra Turajlic,
  12. on behalf of EXACT consortium2,
  13. Aisling Carr1
  1. 1MRC Centre for Neuromuscular Diseases, UCL Queen Square Institute of Neurology
  2. 2The Royal Marsden Hospital and The Institute of Cancer Research
  3. 3Brain Tumour Service (Neuro-oncology), National Hospital for Neurology and Neurosurgery
  4. 4Institute of Immunity and Transplantation, University College London


Immune checkpoint inhibitors (ICI), monoclonal antibodies enhancing T cell responses against tumour cells, have revolutionised the treatment of cancers such as advanced melanoma, leading to enhanced survival. Their action, however, is not tumour-specific, and patients can develop multisystem immune related adverse events (irAE). Neurological irAEs have been reported in 1–14% of patients, depending upon the ICI used, and can affect any part of the neuro-axis. A recent case series from the Royal Marsden Hospital (RMH) identified 10 patients with neurotoxicity following ICI for advanced melanoma between 2010–15, specifically neuropathy (6), plexopathy (1) and aseptic meningitis (3). Exactly how neurological injury occurs, whether cell-, cytokine- or antibody-mediated, is unknown.

We present early data from a newly established collaboration with RMH, aiming to clinically characterize these patients, and identify the cause of neurological injury. To date, we have advised on patients (age range 53–80) with myositis, Guillain-Barré (GBS)-like neuropathy, plexopathy, aseptic meningitis, and encephalitis following ICI (ipilimumab and/or nivolumab) for advanced melanoma. Features common to these patients include their subacute onset, time from ICI administration, and steroid responsiveness (including in GBS-like cases). The incidence of neurological irAEs following ICI will rise with increasing use, and is therefore of concern to practicing neurologists.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.